Don't Put CareDX Stock in Your Portfolio's Pipeline

On the surface, there’s a lot to like about CareDX (NASDAQ:CDNA) stock. It’s a company that’s based on a concept you might find intriguing” transplant diagnostics.

However, getting from concept to execution, and then profitability, is a different story entirely. Sorry to be the bearer of bad news, but CDNA stock gets a “D” rating because frankly, the company’s financials are far from ideal.

CareDX strives to make each step of the transplant process easier. It’s hard not to root for a company that’s helping patients in need of an organ transplant.

However, as investors we sometimes have to separate our feelings about a company from practical considerations. If CareDX can’t capture profits from its transplant diagnostics business, then cautious investors should probably find another company to wager their hard-earned money on.

What’s Happening with CDNA Stock?

Just a quick glance at the history of CDNA stock tells a grim story. The shares were valued at $90+ in the summer of 2021 but recently dropped to just below $16.

There’s no dividend to speak of here, so there’s no consolation prize for CareDX’s downtrodden investors. Before we abandon this company completely, though, let’s at least be fair and learn about what CareDX has to offer.